T-Knife Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$110M
- Investors
-
12
T-Knife Therapeutics General Information
Description
Developer of T cell receptor therapies designed to treat cancer. The company's therapies use a humanized TCR mice platform to carry human gene loci and recombine a broad repertoire of human, enabling doctors and clinicians with an efficient generation and virtual selection of cell receptors for any human tumor antigen.
Contact Information
Website
www.t-knife.comCorporate Office
- Robert-Rössle-Straße 10
- 13125 Berlin
- Germany
Corporate Office
- Robert-Rössle-Straße 10
- 13125 Berlin
- Germany
T-Knife Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 02-Aug-2021 | $110M | Completed | Clinical Trials - Phase 1 | ||
| 4. Later Stage VC | 06-Aug-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 2. Seed Round | 14-Mar-2018 | $9.9M | $9.9M | Completed | Clinical Trials - Phase 1 | |
| 1. Spin-Off | 27-Aug-2015 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
T-Knife Therapeutics Comparisons
Industry
Financing
Details
T-Knife Therapeutics Competitors (6)
One of T-Knife Therapeutics’s 6 competitors is TILT Biotherapeutics, a Venture Capital-Backed company based in Helsinki, Finland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TILT Biotherapeutics | Venture Capital-Backed | Helsinki, Finland | ||||
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| ImCheck Therapeutics | Formerly VC-backed | Marseille, France | ||||
| MediGene | Formerly VC-backed | Planegg, Germany | ||||
| iRepertoire | Corporation | Huntsville, AL |
T-Knife Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T-Knife Therapeutics Patents
T-Knife Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026167093-A1 | A chimeric human cd 95 switch receptor, t-cells expressing the cd 95 switch receptor, vectors with nucleic acids encoding for the cd 95 receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy | Pending | 05-Feb-2025 | ||
| WO-2026167079-A1 | A chimeric human receptor, a nucleic acid encoding the chimeric human receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease | Pending | 05-Feb-2025 | ||
| WO-2026167100-A1 | Antigen recognizing construct capable of binding to a preferentially expressed antigen in melanoma (prame) peptide and a t cell receptor (tcr) having antigenic specificity for prame for use in a method of treating a disease in a subject as well as corresponding t-cells, nucleic acid sequences, vectors, pharmaceutical compositions and kits | Pending | 05-Feb-2025 | ||
| AU-2025234843-A1 | A chimeric programmed cell death protein 1 receptor | Pending | 13-Mar-2024 | ||
| WO-2025190565-A1 | A chimeric programmed cell death protein 1 receptor | Pending | 13-Mar-2024 | C07K14/70532 |
T-Knife Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
T-Knife Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CaaS Capital Management | Hedge Fund | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Qatar Investment Authority | Sovereign Wealth Fund | Minority |
T-Knife Therapeutics FAQs
-
When was T-Knife Therapeutics founded?
T-Knife Therapeutics was founded in 2015.
-
Where is T-Knife Therapeutics headquartered?
T-Knife Therapeutics is headquartered in Berlin, Germany.
-
What is the size of T-Knife Therapeutics?
T-Knife Therapeutics has 40 total employees.
-
What industry is T-Knife Therapeutics in?
T-Knife Therapeutics’s primary industry is Biotechnology.
-
Is T-Knife Therapeutics a private or public company?
T-Knife Therapeutics is a Private company.
-
What is T-Knife Therapeutics’s current revenue?
The current revenue for T-Knife Therapeutics is .
-
How much funding has T-Knife Therapeutics raised over time?
T-Knife Therapeutics has raised $196M.
-
Who are T-Knife Therapeutics’s investors?
CaaS Capital Management, Casdin Capital, EQT Life Sciences, Fidelity Management & Research Company, and Qatar Investment Authority are 5 of 12 investors who have invested in T-Knife Therapeutics.
-
Who are T-Knife Therapeutics’s competitors?
TILT Biotherapeutics, Autolus, ImCheck Therapeutics, MediGene, and iRepertoire are some of the 6 competitors of T-Knife Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
